Key takeaways
Emgality (galcanezumab) and Ubrelvy (ubrogepant) are both medications used to treat migraines, but they work in different ways and are used for different purposes. Emgality is a monoclonal antibody that prevents migraines and treats episodic cluster headaches by blocking the calcitonin gene-related peptide (CGRP) ligand. It is administered as a monthly subcutaneous injection. Ubrelvy, on the other hand, is a CGRP receptor blocker used to treat sudden migraine attacks in adults. It is taken orally, with a typical dose of 50 mg to 100 mg, and can be taken up to twice a day. Both are only available as brand-name medications. Common side effects of Emgality include injection site reactions and sore throat, while Ubrelvy may cause nausea, sleepiness, and dry mouth. Additionally, Ubrelvy has many drug interactions, so you should inform your prescriber about all medications you are taking. Emgality is not known to have many interactions but can cause serious allergic reactions.
